Nuvation Bio Inc. (NUVB)
- Previous Close
2.1500 - Open
2.1800 - Bid 2.2100 x 4000
- Ask 2.2100 x 4000
- Day's Range
2.1000 - 2.2299 - 52 Week Range
1.5400 - 3.9700 - Volume
2,311,539 - Avg. Volume
3,006,863 - Market Cap (intraday)
745.176M - Beta (5Y Monthly) 1.42
- PE Ratio (TTM)
-- - EPS (TTM)
-2.2000 - Earnings Date Aug 4, 2025 - Aug 8, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
7.83
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutic candidates for oncology. Its lead product candidate is taletrectinib, an ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. The company is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 2 clinical trials; NUV-1511, a drug-drug conjugate for use in chemotherapy agent that suppresses the growth of various advanced solid tumors; and NUV-868, a binding domain 2 bromodomain and extra-terminal inhibitor that inhibits bromodomain-containing protein 4. The company was founded in 2018 and is headquartered in New York, New York.
www.nuvationbio.comRecent News: NUVB
View More
Performance Overview: NUVB
Trailing total returns as of 5/13/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NUVB
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NUVB
View MoreValuation Measures
Market Cap
731.57M
Enterprise Value
281.30M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
58.60
Price/Book (mrq)
1.74
Enterprise Value/Revenue
25.67
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-23.33%
Return on Equity (ttm)
-119.66%
Revenue (ttm)
10.96M
Net Income Avi to Common (ttm)
-606.38M
Diluted EPS (ttm)
-2.2000
Balance Sheet and Cash Flow
Total Cash (mrq)
461.68M
Total Debt/Equity (mrq)
2.72%
Levered Free Cash Flow (ttm)
-64.76M
Research Analysis: NUVB
View MoreResearch Reports: NUVB
View MoreDaily – Vickers Top Buyers & Sellers for 04/09/2025
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 04/11/2022
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 12/20/2021
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 12/13/2021
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.